Metabotrophic glutamate receptor 5 modulators and methods use thereof

• US 10,196,399 B2
• Filed: 06/16/2017
• Issued: 02/05/2019
• Est. Priority Date: 06/08/2011
• Status: Active Grant

• Current Assignee: Sunovion Pharmaceuticals Inc. (Sumitomo Chemical Company Limited)
• Original Assignee: Sunovion Pharmaceuticals Inc. (Sumitomo Chemical Company Limited)
• Inventors: Heffernan, Michele L. R., Hardy, Larry Wendell, Wu, Frank Xinhe, Saraswat, Lakshmi D., Spear, Kerry L.
• Primary Examiner(s): Rao, Deepak R
• Assistant Examiner(s): Daniel, Laura M
• Application Number:
  US15/625,604
• Publication Number:
  US 20180037585A1
• Time in Patent Office: 599 Days
• Field of Search: None
• CPC Class Codes: C07D 471/04 Ortho-condensed systems
• CPC Class Codes: C07D 471/14 Ortho-condensed systems
• CPC Class Codes: C07D 471/20 Spiro-condensed systems
• CPC Class Codes: C07D 487/04 Ortho-condensed systems
• CPC Class Codes: C07D 487/10 Spiro-condensed systems
• CPC Class Codes: C07D 487/14 Ortho-condensed systems
• CPC Class Codes: C07D 487/18 Bridged systems
• CPC Class Codes: C07D 491/147 the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
• CPC Class Codes: C07D 491/20 Spiro-condensed systems
• CPC Class Codes: C07D 491/22 in which the condensed system contains four or more hetero rings
• CPC Class Codes: C07D 498/04 Ortho-condensed systems

Abstract

Compounds that modulate GluR5 activity and methods of using the same are disclosed.

Claims

1. A compound of formula (I) or a pharmaceutically acceptable salt thereof:

6. A pharmaceutical composition, comprising a therapeutically effective amount of a compound according to claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

7. A method of treating psychosis, comprising the step of administering a therapeutically effective amount of a compound according to claim 1, or a pharmaceutically acceptable salt thereof, to a subject in need thereof.

8. A method of treating schizophrenia, comprising the step of administering a therapeutically effective amount of a compound according to claim 1, or a pharmaceutically acceptable salt thereof, to a subject in need thereof.

9. A method of treating Alzheimer'"'"'s disease, comprising the step of administering a therapeutically effective amount of a compound according to claim 1, or a pharmaceutically acceptable salt thereof, to a subject in need thereof.

2. A compound of formula (II) or a pharmaceutically acceptable salt thereof:

3. A compound of formula (IV) or a pharmaceutically acceptable salt thereof:

4. A compound of formula (V) or a pharmaceutically acceptable salt thereof:

5. A compound selected from: